Clinical Trial Update: ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating ZEN003694 in combination with niraparib for metastatic or recurrent solid tumors, including ovarian cancer, has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Solid Tumors

Drugs mentioned

• Niraparib (Niraparib)
• ZEN003694

Snippet

Sponsor: Haider Mahdi | Conditions: Ovarian Cancer, Recurrent Solid Tumors | Phase 1 | Status: WITHDRAWN